Pipeline Molecules

At Genentech BioOncology, we are on the cutting edge of cancer research, as evidenced by our robust product pipeline of innovative molecules designed to target cancer through specific molecular processes.

Click here to see a full list of the pipeline molecules currently in development at Genentech/Roche.

Select any of the pipeline molecules below to learn more:

  • Akt Inhibitor (GDC-0068)

    Learn more about the mechanisms by which the Akt Inhibitor GDC-0068 may promote apoptosis and growth arrest in cancer cells.

  • Anti-EGFL7

    Learn more about how the anti-EGFL7 antibody may inhibit critical cellular processes associated with tumor angiogenesis.

  • Anti-HER3/EGFR MAb (MEHD7945A)

    Anti-HER3/EGFR is a MAb with dual binding specificity. Learn how targeting 2 receptors simultaneously may inhibit multiple cancer signaling pathways.

  • Bcl-2-Specific-Inhibitor (GDC-0199)

    GDC-0199 is a small-molecule Bcl-2 inhibitor. Find out how inhibiting Bcl-2 may elicit cancer cell apoptosis.

  • MEK Inhibitor (GDC-0973)

    GDC-0973 is a potent inhibitor of MEK activity. Learn more about how targeting MEK may help overcome activating mutations upstream in the MAPK cascade.

  • Onartuzumab (MetMAb)

    MetMAb is a monovalent antibody designed to bind to and block activation of Met. Learn how blockade of Met may inhibit cancer cell growth, survival, and metastasis.

  • PI3K Inhibitor (GDC-0941)

    Learn more about how GDC-0941 may affect tumor cell growth and viability by inhibiting PI3K signaling.

  • PI3K/mTOR Inhibitor (GDC-0980)

    Learn more about how the dual blockade of mTOR and PI3K may lead to growth arrest and apoptosis in cancer cells.